3i is a lead investor in immatics; a Tuebingen, Germany-based company with a cutting edge platform to design cancer vaccines. Immatics has developed peptide-based active immunotherapy targets at unprecedented speed and efficiency and it's vaccines are designed to have less severe side effects than currently available treatment options. The lead vaccine candidate is in phase II clinical trials for renal cell carcinoma having shown promising data in early clinical trials.